Surfing NASH highlights key moments from its coverage of a watershed moment for Fatty Liver at NASH-TAG 2023. In this conversation, Donna Cryer and Roger Green share impressions from the regulatory viewpoint.
Surfing NASH highlights key moments from its coverage of a watershed moment for Fatty Liver at NASH-TAG 2023. In this conversation, patient advocates Michael Betel and Tony Villiotti join Louise Campbell and Roger Green to share impressions from a momentous conference.
This week’s conversation series continues on the theme of reviewing NASH-TAG 2023, a watershed moment for Fatty Liver disease. For this wrap-up feature, Amy Articolo and Naim Alkhouri join Jörn Schattenberg and Roger Green to illustrate their enthusiasm coming out of the conference.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Caitlin Schneider (Sonic Incytes) joins Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Jerry Mabary (Chronwell) joins Roger Green to explore questions around biopsy, patient centricity, the role of digital tools and combination therapy
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Pamela Danagher (Terns Pharma) joins Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. Respectively, Pamela Danagher (Terns Pharma), Jerry Mabary (Chronwell) and Caitlin Schneider (Sonic Incytes) join Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
Surfing NASH presents an exclusive interview with Dean Tai, Co-Founder and CSO of global-leading AI digital pathology provider HistoIndex. Dean joins Co-Surfers Jörn Schattenberg and Roger Green to discuss the application and compelling results of AI-assisted histologic assessment of Phase 2 trials on aldafermin and resmetirom.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Donna Cryer and Roger Green share impressions from the regulatory viewpoint.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Naim Alkhouri, Amy Articolo, Jörn Schattenberg and Roger Green explore key takeaways, insights on the F3 population and using AI-assisted assessment to improve those therapeutic efficacy.
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make
